MNG454
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- TNFA_SIGNALING_VIA_NFKB+0.374
- WNT_BETA_CATENIN_SIGNALING+0.366
- UV_RESPONSE_DN+0.342
- PROTEIN_SECRETION+0.320
- HEDGEHOG_SIGNALING+0.319
- MITOTIC_SPINDLE+0.295
- TGF_BETA_SIGNALING+0.294
- ANDROGEN_RESPONSE+0.270
- HYPOXIA+0.270
- IL2_STAT5_SIGNALING+0.209
Top 10 suppressed
- MYC_TARGETS_V2-0.489
- OXIDATIVE_PHOSPHORYLATION-0.466
- REACTIVE_OXYGEN_SPECIES_PATHWAY-0.352
- MYC_TARGETS_V1-0.276
- PANCREAS_BETA_CELLS-0.249
- DNA_REPAIR-0.216
- CHOLESTEROL_HOMEOSTASIS-0.179
- FATTY_ACID_METABOLISM-0.166
- COAGULATION-0.159
- ADIPOGENESIS-0.157
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | MNG435 | — | — | 0.819 |
| 2 | MNG609 | — | — | 0.808 |
| 3 | MNG1025 | — | — | 0.808 |
| 4 | TCGA-AR-A24O-01A-11R-A169-07 | — | A | 0.797 |
| 5 | TCGA-60-2704-01A-11R-2045-07 | — | cohortSQ1 | 0.786 |
| 6 | SAMN03290934 | — | — | 0.784 |
| 7 | MNG78 | — | — | 0.782 |
| 8 | TCGA-AQ-A1H3-01A-31R-A13Q-07 | — | A | 0.779 |
| 9 | d719788d-0c64-4488-bb84-ab5536d31a03 | — | — | 0.769 |
| 10 | MNG530 | — | — | 0.764 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 29 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| TNFA_SIGNALING_VIA_NFKB | 0.374 | Inavolisib | — uncovered |
| WNT_BETA_CATENIN_SIGNALING | 0.366 | Inavolisib | — uncovered |
| UV_RESPONSE_DN | 0.342 | Inavolisib | — uncovered |
| PROTEIN_SECRETION | 0.320 | Remibrutinib | — uncovered |
| HEDGEHOG_SIGNALING | 0.319 | Inavolisib | — uncovered |
| MITOTIC_SPINDLE | 0.295 | Inavolisib | — uncovered |
| TGF_BETA_SIGNALING | 0.294 | Inavolisib | — uncovered |
| ANDROGEN_RESPONSE | 0.270 | Inavolisib | — uncovered |
| HYPOXIA | 0.270 | Idelalisib | — uncovered |
| IL2_STAT5_SIGNALING | 0.209 | Idelalisib | — uncovered |
| ANGIOGENESIS | 0.182 | Remibrutinib | — uncovered |
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.157 | Inavolisib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.149 | Idelalisib | — uncovered |
| INTERFERON_ALPHA_RESPONSE | 0.141 | Inavolisib | — uncovered |
| APOPTOSIS | 0.123 | Idelalisib | — uncovered |
| APICAL_SURFACE | 0.118 | Temsirolimus | — uncovered |
| KRAS_SIGNALING_UP | 0.109 | Inavolisib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.104 | Inavolisib | — uncovered |
| ALLOGRAFT_REJECTION | 0.069 | Idelalisib | — uncovered |
| P53_PATHWAY | 0.059 | Idelalisib | — uncovered |